Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986148

Drug Profile

BMS 986148

Alternative Names: BMS-986148; Mesothelin-ADC - BMS

Latest Information Update: 22 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Peptides
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Nov 2021 Bristol-Myers Squibb terminates phase I/IIa trial in Gastric cancer, Ovarian cancer, Non small cell lung cancer, Mesothelioma, Pancreatic cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Australia, Belgium, Italy, Canada, Netherlands, United Kingdom and USA (EudraCT2014-002485-70) (NCT02341625)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Japan (IV, Injection)
  • 28 Oct 2019 Preliminary adverse events, efficacy and pharmacokinetics data from a phase I/II trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019 (AACR-NCI-EORTC-2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top